Company: SVREW
Filing Date: 2025-03-31
Form Type: F-1
Source: 0001213900-25-026272
Chunk: 6

Company: SaverOne 2014 Ltd.
Filing Date: 2025-03-31
Form: F-1
Chunk 6
---
 ADSs by Yorkville and any discounts, commissions, or concessions received by Yorkville
are deemed to be underwriting discounts and commissions under the Securities Act.

Our ordinary shares are listed
on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol “SVRE.” The last reported sale price of our ordinary shares
on the TASE on March 30, 2025, was NIS 0.01 or $0.0027 per share (based on the exchange rate reported by the Bank of Israel on that date,
which was NIS 3.684 = $1.00).

Our ADSs are listed on the
Nasdaq Capital Market, or Nasdaq, under the symbol “SVRE. The last reported sale price of our ADSs on Nasdaq on March 28, 2025,
was $3.215 per ADS.

We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. You should read this entire prospectus and any amendments
or supplements carefully before you make your investment decision.

We are both an “emerging
growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, a “foreign private issuer,”
as defined under the U.S. federal securities laws, and as such, are eligible for reduced public company reporting requirements. See “Prospectus
Summary—Implications of Being an Emerging Growth Company and a Foreign Private Issuer” for additional information.

Investing in our securities involves a high degree of risk. See“Risk Factors” beginning on page 9 of this prospectus.

Neither the Securities and Exchange Commission (“SEC”), the Israel Securities Authority nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is _____, 2025

Table of Contents</div>

| Prospectus Summary                                   |     |  1 |
| The Offering                                         |     |  7 |
| Risk Factors                                         |     |  9 |
| Cautionary Note Regarding Forward-Looking Statements |     | 12 |
| The Yorkville Transaction                            |     | 13 |
| Use Of Proceeds                                      |     | 16 |
| Capitalization                                       |     | 17 |
| Selling Shareholder                                  |     | 18 |
| Description of